 |
Dr. H. Richard Alexander Jr. - Baltimore, Maryland
-
Dr. Alexander is an internationally recognized cancer surgeon and surgical
oncologist at the University of Maryland Marlene and Stewart Greenebaum
Cancer Center. He is also the associate chairman for clinical research
in the University of Maryland Department of Surgery. His research interests
include perfusion techniques to treat patients with advanced cancers of
the limb, liver, and peritoneal cavity. Dr. Alexander was formally the
deputy director of the NCI's Center for Cancer Research.
University of Maryland Medical Center
Greenebaum Cancer Center
22 S. Greene Street
Baltimore, MD 21201
Phone: 410.605.7233 (VA Baltimore)
email: HRAlexander@smail.umaryland.edu
Baltimore VA Medical Center
10 North Greene Street
Baltimore, MD 21201
(410) 605-7000
800-463-6295
http://www.umm.edu/news/releases/hr_alexander.html
|
 |
Dr. Robert Cameron - Los Angeles, California
- Dr. Cameron is a surgical oncologist with expertise in treating mesothelioma
patients at the UCLA Medical School.
- Dr. Robert Cameron is a member of the Scientific Advisory Board for the
Pacific Heart, Lung, & Blood Institute (PHLBI, www.phlbi.org). Dr.
Cameron has been at the forefront of developing innovative therapies for
extending the lives of mesothelioma patients. Dr. Cameron's research
plan for PHLBI includes programs involving Immunotherapy and Screening/Early
Detection/Prevention. Dr. Cameron's research plan also includes investigation
into much-needed administrative improvements in medical care which will
provide patients with additional knowledge, security, and control regarding
their treatment.
-
11818 Wilshire Blvd., Suite 200
Los Angeles, California 90025
Phone: 310.794.7333 or 310.231.2130
email: rcameron@mednet.ucla.edu.
- "Improved Survival with Interferon Alpha Maintenance Therapy Following
pleurectomy / decortication and Radiation for Malignant Pleural Mesothelioma,"
as presented by Dr. Robert Cameron to the Society of Thoracic Surgeons,
January 30, 2006.
- EPP vs P/D: The Great Debate. Dr. Cameron favors the Pleurectormy/Decortication
(10/29/06)
- Anatomy of a Successful P/D (photos). Dr. Robert Cameron, September 13, 2005
-
"Rational Versus Radical Therapy For Mesothelioma: A New Approach,"
Dr. Robert Cameron, UCLA Medical School, presented at MARF Symposium in
Las Vegas, October 16, 2004.
Copyright
of Dr. Robert Cameron. Do not copy without permission (11/18/04)
- UCLA Proposes Comprehensive Mesothelioma Translational Research Program (5/10/04)
|
 |
Dr. Alexander Farivar - Seattle, Washington
- Dr. Farivar is the Director of Pleural Disease at the Swedish Cancer Institute
in Seattle. He has expertise in Esophageal and Thoracic Surgery at the
Swedish Cancer Institute in Seattle.
-
Swedish Cancer Institute
1221 Madison Street suite 400
Seattle, WA 98104
Phone: 206.215.6800
|
no photo available
|
Dr. David
Jablons - San Francisco, California
-
Mt. Zion Medical Center/USCF
2330 Post Street, Suite 420
San Francisco, CA 94143-1674
Phone: 415.885.3882
email
: djablons@mzsurgery.his.ucsf.edu
-
West Coast Medical Expert Update
: Dr. David Jablons, San Francisco, CA.
- Resection and Intraoperative Radiotherapy (IORT) followed by Three Dimensional
Conformal Radiotherapy +/- Adjuvant Chemotherapy for Malignant Mesothelioma.
- In vitro and in vivo expression of IL-4 receptors on human malignant mesothelioma:
implications for therapy.
|
 |
Dr. Larry Kaiser - Philadelphia, Pennsylvania
-
Dr. Kaiser is a cardiothoracic surgeon at the University of Pennsylvania
Center for Lung Cancer & Related Disorders.
University of Pennsylvania
4th Floor, Philadelphia, PA 19104.
Phone: 215.662.7538;
email: Kaiser@mail.med.upenn.edu.
http://www.uphs.upenn.edu/surgery/faculty/lrk.html
|
 |
Dr. Brian Loggie - Omaha, Nebraska
-
Dr. Loggie is Professor of Surgery and Director for:
Cancer Center
Creighton University Medical Center
601 N. 30th St, Suite 3700
Omaha, NE 68131
Phone: 420-280-4100
email: bwl01656@creighton.edu
- Treatment and Prevention of Malignant Ascites Associated with Disseminated
Intraperitoneal Malignancies by Aggressive Combined-Modality Therapy (9/29/04)
- Intraperitoneal Hyperthermic Chemotherapy (IPHC) for Peritoneal Carcinomatosis
and Malignant Ascites. Creighton University Medical Center (CUMU) Cancer
Center (9/29/04)
- http://www.help4cancer.com
- "Promising" Results from Peritoneal Mesothelioma Studies at NCI
and Wake Forest, December 20, 1997
|
 |
Dr. Harvey
Pass - New York, New York
- Dr. Harvey Pass is Professor and Chief of the Division of Thoracic Surgery
and Thoracic Oncology at the New York University School of Medicine and
Comprehensive Cancer Center. Dr. Pass has studied pleural mesothelioma
since 1988 when he was the Head of Thoracic Oncology and Senior Investigator
of the Surgery Branch of the National Cancer Institute in Bethesda. Dr.
Pass combines cytoreductive surgery, either EPP or pleurectomy, with innovative
or standard adjuvant therapies including novel antiangiogenesis inhibitors
postoperatively or chemotherapy combinations. His Thoracic Oncology laboratory
is pursuing the study of proteins (proteomics) and gene expression profiles
in mesothelioma to develop new early detection strategies, as well as
designing alternate innovative treatments which use novel proteins as
targets for mesothelioma.
- Curriculum Vitae (resume), Dr. Harvey Pass. March 26, 2003
- Dr. Pass is the Chairman of the Science Advisory Board of the Mesothelioma
Applied Research Foundation (MARF).
-
Professor and Chief, Division of Thoracic Surgery and Thoracic Oncology
Department of Cardiothoracic Surgery
NYU School of Medicine and Comprehensive Cancer Center
530 1
st Avenue, 9V
New York, New York 10016
Phone: 212.263.7417
email: passh01@med.nyu.edu
- Malignant Pleural Mesothelioma: Surgical Roles and Novel Therapies, preface
by RGW (2/7/02)
- Photo Dynamic Therapy, Surgery by Dr. Harvey Pass and Chemotherapy Help
35 Year Old's Battle Against Mesothelioma
- Preoperative Tumor Volume is Associated With Outcome in MM, (2/8/98)
- Update on Dr. Harvey Pass' Research: (10/6/97)
|
 |
Dr. Lary A. Robinson - Tampa, Florida
- Dr. Robinson is a thoracic surgical oncologist with expertise in treating
mesothelioma patients.
-
Dr. Robinson is on the Science Advisory Board of the Mesothelioma Applied
Research Foundation (MARF).
H. Lee Moffitt Cancer Center & Research Institute
12902 Magnolia Drive
Tampa, Florida 33612-9497
Phone: 813.979.3050
email: robinson@moffitt.usf.edu.
http://www.moffitt.usf.edu
- Thoracic Surgeon, H. Lee Moffitt Cancer Center & Research Institute,
Tampa, Florida
|
no pho to available
|
Dr. Valerie Rusch - New York, New York
-
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10021
Phone: 212.639.5873
email: ruschv@mskcc.org
-
Memorial Sloan-Kettering Cancer Center in New York City.
http://www.mskcc.org
|
 |
Dr. W. Roy Smythe - Temple, Texas
- Dr. W. Roy Smythe is involved in the surgical diagnosis and treatment of
mesothelioma patients. He has designed a pilot protocol at M. D. Anderson
for malignant pleural mesothelioma involving aggressive surgical therapy
followed by intensity modulated radiation therapy (IMRT). In the laboratory,
he was involved in the initial research work evaluating gene therapy for
this disease in the mid 1990's at the University of Pennsylvania.
He is currently evaluating a number of novel gene therapy and molecular
approaches to the treatment of this disease, and hopes to bring one or
more of these to the clinic in the next year.
-
Curriculum Vitae (resume), Dr. W.Roy Smythe. October 16, 2001
- Dr. Smythe is on the Science Advisory Board of the Mesothelioma Applied
Research Foundation (MARF).
- Preclinical Data of Introgen's INGN 241 Demonstrate Broad Anti-Cancer
Activity In Multiple Tumor Types as Monotherapy and in Combination; Update
on Gene Therapy Research at MDA under Dr. Roy Smythe (6/14/01)
-
Dr. W. Roy Smythe
Professor & Chairman
Texas A&M University Health Sciences Center
Scott & White Hospital and Clinic
Department of Surgery
2401 South 31st Street
Temple, TX 76501
Phone: 254.724.2595
Fax: 254.724.2786
email: rsmythe@swmail.sw.org
|
 |
Dr. DavidSugarbaker - Boston, Massachusetts
-
Dr. Sugarbaker is a surgical oncologist with expertise in treating mesothelioma
patients. Dr. Sugarbaker has pioneered the "tri-modal" therapy approach.
Brigham & Womens Hospital
75 Francis Street, Boston
Massachusetts 02115
Phone: 617.732.6824
email: djsugarbak@bic.bwh.havard.edu.
- Multimodality Management of MM: Dr. David Sugarbaker, January 1999
-
Current Therapy for Mesothelioma, Sugarbaker et al, 1997
The
Division of Thoracic Surgery at the Brigham and Women's Hospital in Boston Massachusetts provides diagnostic and treatment services to
patients with benign and malignant neoplasms and other disorders of the
lung, esophagus, mediastinum and chest wall. Their website provides complete
review of services available, how to set up an appointment, whom to call,
and how to prepare for surgery and rehabilitate afterwards. Check it out.
http://www.chestsurg.org
|
no photo available
|
Dr. Paul Sugarbaker- Washingon , D. C.
-
Sugarbaker Oncology Associates, P.C.
110 Irving St., NW
Washington, DC 20010
Phone: 202.877.3908
email: n/a
- Sugarbaker Oncology Associates, Washington Cancer Institute, Washington
Hospital Center, Washington, D.C. "We specialize in the surgical
treatment of cancers that arise in the gastrointestinal tract, such as
abdominal (Peritoneal) mesotheliomas."
|
 |
Dr. Robertt Taub - New York, New York
- Dr. Taub is a medical oncologist who directs the Connective Tissue Oncology
Program at the Herbert Irving Comprehensive Cancer Center, where there
are a number of ongoing multimodality studies of patients with pleural
and peritoneal mesothelioma.
-
Dr. Taub is on the Science Advisory Board of the Mesothelioma Applied Research
Foundation (MARF).
Columbia University College of Physicians and Surgeons
161 Fort Washington Avenue
New York, New York 10032
Phone: 212.305.4076
email: rnt1@columbia.edu
- Phase II Trial of Combined Resection, Intraperitoneal Chemotherapy, and
Whole Abdominal Radiation for Treatment of Peritoneal Mesothelioma (11/14/01)
- New Trial Using Tri-Modal Therapy for Peritoneal Mesothelioma in New York
with Dr. Robert N. Taub.
|
 |
Dr. Eric Vallieres - Seattle, Washington
- Dr. Vallières is a surgical oncologist who since 1997 has been the
principal investigator of a Phase II multi-modal trial for mesothelioma
patients at the University of Washington Medical Center. He now practices
at the Swedish Cancer Institute.
-
Dr. Vallières is on the Science Advisory Board of the Mesothelioma
Applied Research Foundation (MARF).
University of Washington School of Medicine
Eric Vallières MD FRCSC
Thoracic Oncology
Swedish Cancer Institute
1221 Madison Street suite 400
Seattle, WA 98104
Phone: 206.-215.6800
Fax: 206.215.6801
email:
eric.vallieres@swedish.org
- Dr. Eric Vallières: Engaged on all Fronts. Seattle, Washington
|
|
|
 |
Dr. ClaireVerschraegen - Burlington, VT
- Dr. Verschraegen is the Professor of Medicine and Director of the Hemotology/Oncology
Division at the University of Vermont.
-
Dr. Verschraegen was on the Science Advisory Board of the Mesothelioma
Applied Research Foundation (
MARF).
-
Hematology/Oncology Division
UVM Given College of Medicine Building
89 Beaumont Avenue, Suite E-214
Burlington, VT 05405, USA
Phone: (802) 656-5487
email
: Claire.Verschraegen@uvm.edu
|
 |
Dr. Nicholas Vogelzang - Las Vegas, Nevada
- Dr. Vogelzang is a thoracic surgical oncologist with interests in clinical
trials in genitourinary malignancies and mesothelioma. He is a recognized
expert in new therapies for patients with metastatic kidney cancer, including
genetic therapy, new cytokine therapy, and combination.
- Therapeutic Progress in Malignant Mesothelioma by Nicholas J. Vogelzang,
MD. A summary of the diagnosing, staging, treatment approaches (including
pemetrexed) and additional trials. (4/27/05)
-
Dr. Vogelzang is on the Board of Directors of the Mesothelioma Applied
Research Foundation (
MARF).
Nevada Cancer Institute
10000 W.Charleston Blvd., Suite 260
Las Vegas, NV 89135
Phone: 702.821.0000
email nvogelza@nvcancer.org
www.nevadacancerinstitute.org
-
ASCO Reports on Intracavitary Hyperthermic Chemo, FDG-PET Scan Prognostication, and
Alimta/Cisplatin Quality of Life (6/12/03)
-
Unresectable Mesothelioma: A New Standard of Care (5/29/02)
"Mesothelioma of the pleura, peritoneum,pericardium, and tunica vaginalis
is a very rare malignancy which takes the lives of 3-5 wonderful people
per day in the USA. It cause significant suffering, pain, shortness of
breath, abdominal bloating and weight loss which are often resistant to
all medical care. It is a disease which most medical,surgical and radiation
oncologists have little or no experience in treating due to its rarity,
and sadly many such physicians do not wish to become involved in the treatment
of the disease because treatments have been so ineffective. In spite of
this sad state of affairs a few oncologists have worked and struggled
for the past 10-20 years to improve the care and outcome of such patients.
We are delighted to finally have a support group such as MARF helping
with the struggle. Just as the breast, prostate and colon cancer support
groups have mobilized research funds, so MARF will do. Patients and their
families must get involved and MARF is a way for them to do so."
Dr. Nicholas Vogelzan
|
|
|
|